#United States #Palo Alto #iPS Cells #I Peace #NKT Cells

I Peace Breaks Ground with Human iPS Cells from NKT Cells

I Peace, Inc., a pioneering GMP cell therapy CDMO based in Palo Alto, California, has recently marked a significant advancement in the field of regenerative medicine and cell therapy. The company has successfully developed human induced pluripotent stem (iPS) cells using NKT cells, a type of immune cell known for its important roles in various health conditions, including cancer, infectious diseases, and autoimmune disorders. This innovative approach is expected to fuel advances in research and therapies that utilize immune mechanisms.

The Technology Behind the Breakthrough

Utilizing proprietary technology, I Peace has achieved the selective and efficient expansion of NKT cells, leading to the creation of highly uniform and reproducible human iPSCs derived from these important immune cells. Through rigorous genomic PCR analysis, the origin of these iPS cells has been confirmed to be NKT cells, demonstrating the robustness of the developed technology.

The implications of this breakthrough are vast. By leveraging the unique immunological properties of NKT cells, researchers can explore diverse fields such as cancer immunotherapy, infectious disease investigation, immunosenescence studies, and drug discovery. I Peace's accomplishments will undoubtedly pave the way for groundbreaking therapeutic advancements, contributing to a new era of regenerative medicine.

Commitment to GMP Standards

In addition to the foundational research made possible by these iPS cells, I Peace is committed to providing contract manufacturing services in alignment with GMP compliance, adhering to global regulatory standards. This ensures that the iPS cells generated from NKT cells can be provided for research and clinical applications under rigorously controlled conditions.

Looking ahead, I Peace aims to expand its offerings of immune cell-derived iPS cells, thereby enhancing its support for research institutions and companies both in Japan and internationally. The continuous development and supply of these advanced cellular therapies signify a progressive move towards a future where regenerative medicine becomes more accessible.

About I Peace, Inc.

Founded in 2015 by Koji Tanabe, an alum of Professor Shinya Yamanaka’s laboratory at Kyoto University, I Peace is dedicated to increasing access to iPS cell technologies. Tanabe remains at the forefront of iPS cell research, committing daily to innovative advancements that drive the capabilities and availability of these versatile cells.

By ensuring scalable manufacturing processes that mitigate contamination risks and offering affordable solutions for iPS cell production, I Peace propels the drug discovery and cell therapy development sectors forward. Their ultimate vision includes establishing iPS cell banking services for individuals, ensuring that everyone has the opportunity to utilize this remarkable technology for their future healthcare needs.

I Peace’s dedication to maintaining PMDA and FDA standards cements its role as a vital partner for pharmaceutical and cell therapy development entities, enabling expedited availability of lifesaving cell therapies. For more information about their services and technological innovations, visit I Peace, Inc..